[1]许富康,何益平,郭航远,等.经导管主动脉瓣置换术治疗主动脉瓣狭窄应用进展[J].介入放射学杂志,2022,31(10):1020-1026.
　XU Fukang,HE Yiping,GUO Hangyuan,et al.Application progress of transcatheter aortic valve replacement for aortic stenosis[J].journal interventional radiology,2022,31(10):1020-1026.
点击复制

经导管主动脉瓣置换术治疗主动脉瓣狭窄应用进展()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
31
期数:
2022年10
页码:
1020-1026
栏目:
综述
出版日期:
2022-11-07

文章信息/Info

Title:
Application progress of transcatheter aortic valve replacement for aortic stenosis
作者:
许富康;  何益平;  郭航远;  彭 放
Author(s):
XU Fukang;  HE Yiping;  GUO Hangyuan;  PENG Fang.
Department of Cardiology， Shaoxing Municipal People’s Hospital， Shaoxing Hospital of Zhejiang University， Shaoxing， Zhejiang Province 312000， China
关键词:
【关键词】 主动脉瓣狭窄;  经导管主动脉瓣置换术;  进展
文献标志码:
A
摘要:
【摘要】 主动脉瓣狭窄（AS）是在解剖层面导致心脏射血受阻、心脏负荷增加以及冠状动脉、脑血管和全身脏器供血受限的疾病，对患者产生重要影响。随着我国老龄化进程加快，老年主动脉瓣钙化、退变导致AS患者越来越多，针对这类患者采取合适的治疗方案非常重要。AS根本治疗是瓣膜置换。外科主动脉瓣置换术（SAVR）对年轻AS患者耐受性良好，但仍存在创伤大等缺陷，对老年患者风险很高，并发症发生率也很高。微创经导管主动脉瓣置换术（TAVR）是老年AS患者的重要选择。该文就AS，TAVR手术患者、手术入路、人工瓣膜类型选择，术后抗栓策略，术后并发症及其处理及术后康复治疗等应用进展作一综述。

参考文献/References:

［1］ Cribier A， Eltchaninoff H， Bash A， et al. Percutaneous trans- catheter implantation of an aortic valve prosthesis for calcific aortic stenosis- first human case description［J］. Circulation， 2002， 106： 3006- 3008.
［2］ 刘伟丽，付军桦，江 磊，等． 经导管主动脉瓣植入术治疗极高危主动脉瓣重度返流1例［J］． 介入放射学杂志， 2019， 28：823- 825．
［3］ Popma JJ， Reardon MJ， Khabbaz K， et al. Early clinical outcomes after transcatheter aortic valve replacement using a novel self- expanding bioprosthesis in patients with severe aortic stenosis who are suboptimal for surgery： results of the evolut R U.S.study［J］. JACC Cardiovasc Interv， 2017， 10： 268- 275.
［4］ Feldman TE， Reardon MJ， Rajagopal V， et al. Effect of mechanically expanded vs self- expanding transcatheter aortic valve replacement on mortality and major adverse clinical events in high- risk patients with aortic stenosis： the REPRISE Ⅲ randomized clinical trial［J］. JAMA， 2018， 319： 27- 37.
［5］ Leclercq F， Robert P， Akodad M， et al. Prior balloon valvuloplasty versus direct transcatheter aortic valve replacement： results from the DIRECTAVI trial［J］. JACC Cardiovasc Interv， 2020， 13： 594- 602.
［6］ Annabi MS， Cote N， Dahou A， et al. Comparison of early surgical or transcatheter aortic valve replacement versus conservative management in low- flow， low- gradient aortic stenosis using inverse probability of treatment weighting： results from the TOPAS prospective observational cohort study［J］. J Am Heart Assoc， 2020， 9： e017870.
［7］ Wendler O， Dworakowski R， Monaghan M， et al. Direct transapical aortic valve implantation： a modified transcatheter approach avoiding balloon predilatation［J］. Eur J Cardiothorac Surg， 2012， 42： 734- 736.
［8］ Borgermann J， Holzhey DM， Thielmann M， et al. Transcatheter aortic valve implantation using the ACURATE TA system： 1- year outcomes and comparison of 500 patients from the SAVI registries［J］. Eur J Cardiothorac Surg， 2017， 51： 936- 942.
［9］ 乐 健，纪 军，何胜虎． 经颈动脉途径经导管主动脉瓣置换术治疗重度主动脉瓣狭窄一例［J］． 华西医学， 2020， 35：1122- 1126．
［10］ Anselmi A， Tomasi J， Giardinelli F， et al. Safety and effectiveness of the transsubclavian approach for transcatheter aortic valve implantation with the 14- F CoreValve Evolut R device［J］. J Cardiovasc Med（Hagerstown）， 2018， 19： 664- 668.
［11］ Kapadia S， Agarwal S， Miller DC， et al. Insights into timing， risk factors， and outcomes of stroke and transient ischemic attack after transcatheter aortic valve replacement in the PARTNER trial（placement of aortic transcatheter valves）［J］. Circ Cardiovasc Interv， 2016， 9： e002981.
［12］ 梁 影，王 巍，王 旭，等． 经导管主动脉瓣膜置换临床结果及随访分析［J］． 心肺血管病杂志， 2019， 38：247- 251．
［13］ Geisler BP， Jorgensen TH， Thyregod HGH， et al. Cost- effecti- veness of transcatheter versus surgical aortic valve replacement in patients at lower surgical risk： results from the NOTION trial［J］. EuroIntervention， 2019， 15： e959- e967.
［14］ Baron SJ， Wang K， House JA， et al. Cost- effectiveness of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at intermediate risk［J］. Circulation， 2019， 139： 877- 888.
［15］ Iung B， Baron G， Butchart EG， et al. A prospective survey of patients with valvular heart disease in Europe： The Euro Heart Survey on Valvular Heart Disease［J］. Eur Heart J， 2003， 24： 1231- 1243.
［16］ Gao RL. Current status of valvular heart diseasr in China［J］. West China Med J， 2018， 33： 127- 131.
［17］ Gleason TG， Reardon MJ， Popma JJ， et al. 5- year outcomes of self- expanding transcatheter versus surgical aortic valve replacement in high- risk patients［J］. J Am Coll Cardiol， 2018， 72： 2687- 2696.
［18］ Baron SJ， Arnold SV， Reynolds MR， et al. Durability of quality of life benefits of transcatheter aortic valve replacement： long- term results from the CoreValve US extreme risk trial［J］. Am Heart J， 2017， 194： 39- 48.
［19］ Ito S， Nkomo VT， Orsinelli DA， et al. Impact of stroke volume index and left ventricular ejection fraction on mortality after aortic valve replacement［J］. Mayo Clin Proc， 2020， 95： 69- 76.
［20］ Reardon MJ， Kleiman NS， Adams DH， et al. Outcomes in the randomized CoreValve US pivotal high risk trial in patients with a society of thoracic surgeons risk score of 7% or less［J］. JAMA Cardiol， 2016， 1： 945- 949.
［21］ Makkar RR， Thourani VH， Mack MJ， et al. Five- year outcomes of transcatheter or surgical aortic- valve replacement［J］. N Engl J Med， 2020， 382： 799- 809.
［22］ Thourani VH， Kodali S， Makkar RR， et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate- risk patients： a propensity score analysis［J］. Lancet， 2016， 387： 2218- 2225.
［23］ Baron SJ， Arnold SV， Wang K， et al. Health status benefits of transcatheter vs surgical aortic valve replacement in patients with severe aortic stenosis at intermediate surgical risk： results from the PARTNER 2 randomized clinical trial［J］. JAMA Cardiol， 2017， 2： 837- 845.
［24］ 李 捷，孙英皓，李 光，等． 经导管主动脉瓣置换术在外科低危主动脉瓣狭窄患者中的疗效分析［J］． 中国介入心脏病学杂志， 2018， 26：619- 621．
［25］ Mack MJ， Leon MB， Thourani VH， et al. Transcatheter aortic- valve replacement with a balloon- expandable valve in low- risk patients［J］. N Engl J Med， 2019， 380： 1695- 1705.
［26］ Popma JJ， Deeb GM， Yakubov SJ， et al. Transcatheter aortic- valve replacement with a self- expanding valve in low- risk patients［J］. N Engl J Med， 2019， 380： 1706- 1715.
［27］ Baron SJ， Magnuson EA， Lu M， et al. Health status after trans-catheter versus surgical aortic valve replacement in low- risk patients with aortic stenosis［J］. J Am Coll Cardiol， 2019， 74： 2833- 2842.
［28］ Dawson LP， Dagan M， Koh Y， et al. Factors that prevent progression to transcatheter aortic valve implantation（TAVI）［J］. Heart Lung Circ， 2019， 28： 1225- 1234.
［29］ Writing Committee Members， Otto CM， Nishimura RA， et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease： executive summary： a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines［J］. J Am Coll Cardiol， 2021， 77： 450- 500.
［30］ Kirker EB， Hodson RW， Spinelli KJ， et al. The carotid artery as a preferred alternative access route for transcatheter aortic valve replacement［J］. Ann Thorac Surg， 2017， 104： 621- 629.
［31］ Bob- Manuel T， Almusawi H， Rezan T， et al. Efficacy and safety of transcarotid transcatheter aortic valve replacement： a systematic review［J］. Cardiovasc Revasc Med， 2020， 21： 917- 926.
［32］ Gleason TG， Schindler JT， Hagberg RC， et al. Subclavian/axillary access for self- expanding transcatheter aortic valve replacement renders equivalent outcomes as transfemoral［J］. Ann Thorac Surg， 2018， 105： 477- 483.
［33］ Amat- Santos IJ， Rojas P， Gutierrez H， et al. Transubclavian approach： a competitive access for transcatheter aortic valve implantation as compared to transfemoral［J］. Catheter Cardiovasc Interv， 2018， 92： 935- 944.
［34］ Amer MR， Mosleh W， Joshi S， et al. Comparative outcomes of transcarotid and transsubclavian transcatheter aortic valve replacement［J］. Ann Thorac Surg， 2020， 109： 49- 56.
［35］ Reichenspurner H， Schaefer A， Schafer U， et al. Self- Expanding transcatheter aortic valve system for symptomatic high- risk patients with severe aortic stenosis［J］. J Am Coll Cardiol， 2017， 70： 3127- 3136.
［36］ Reardon MJ， Feldman TE， Meduri CU， et al. Two- year outcomes after transcatheter aortic valve replacement with mechanical vs self- expanding valves： The REPRISE Ⅲ Randomized Clinical Trial［J］. JAMA Cardiol， 2019， 4： 223- 229.
［37］ Van Belle E， Vincent F， Labreuche J， et al. Balloon- expandable versus self- expanding transcatheter aortic valve replacement： a propensity- matched comparison from the FRANCE- TAVI registry［J］. Circulation， 2020， 141： 243- 259.
［38］ Abdelghani M， Mankerious N， Landt M， et al. Transcatheter aortic valve implantation with the third generation balloon- expandable bioprosthesis in patients with severe landing Zone Calcium［J］. Am J Cardiol， 2020， 125： 931- 940.
［39］ Abdel- Wahab M， Landt M， Neumann FJ， et al. 5- Year outcomes after TAVR with balloon- expandable versus self- expanding valves： results from the CHOICE randomized clinical trial［J］. JACC Cardiovasc Interv， 2020， 13： 1071- 1082.
［40］ Ichibori Y， Mizote I， Maeda K， et al. Clinical outcomes and bioprosthetic valve function after transcatheter aortic valve implantation under dual antiplatelet therapy vs. aspirin alone［J］. Circ J， 2017， 81： 397- 404.
［41］ Brouwer J， Nijenhuis VJ， Delewi R， et al. Aspirin with or without clopidogrel after transcatheter aortic- valve implantation［J］. N Engl J Med， 2020， 383： 1447- 1457.
［42］ Rodes- Cabau J， Masson JB， Welsh RC， et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a Balloon- Expandable valve： the ARTE（aspirin versus aspirin+clopidogrel following transcatheter aortic valve implantation）randomized clinical trial［J］. JACC Cardiovasc Interv， 2017， 10： 1357- 1365.
［43］ Nijenhuis VJ， Ten Berg JM， Hengstenberg C， et al. Usefulness of clopidogrel loading in patients who underwent transcatheter aortic valve implantation（from the BRAVO- 3 randomized trial）［J］. Am J Cardiol， 2019， 123： 1494- 1500.
［44］ Jimenez DV， Tello- Montoliu A， Moreno R， et al. Assessment of platelet REACtivity after transcatheter aortic valve replacement： the REAC- TAVI trial［J］. JACC Cardiovasc Interv， 2019， 12： 22- 32.
［45］ Kosmidou I， Liu Y， Alu MC， et al. Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve replacement in patients with atrial fibrillation［J］. JACC Cardiovasc Interv， 2019， 12： 1580- 1589.
［46］ Smith CR， Leon MB， Mack MJ， et al. Transcatheter versus surgical aortic- valve replacement in high- risk patients［J］. N Engl J Med， 2011， 364： 2187- 2198.
［47］ De Backer O， Dangas GD， Jilaihawi H， et al. Reduced leaflet motion after transcatheter aortic- valve replacement［J］. N Engl J Med， 2020， 382： 130- 139.
［48］ Van Belle E， Hengstenberg C， Lefevre T， et al. Cerebral embolism during transcatheter aortic valve replacement： the BRAVO- 3 MRI study［J］. J Am Coll Cardiol， 2016， 68： 589- 599.
［49］ Lansky AJ， Brown D， Pena C， et al. Neurologic complications of unprotected transcatheter aortic valve implantation（from the Neuro- TAVI trial）［J］. Am J Cardiol， 2016， 118： 1519- 1526.
［50］ 范嘉祺，刘先宝，朱齐丰，等． 经导管主动脉瓣置换术对心脏传导系统的影响［J］． 心电与循环， 2016， 35：403- 406．
［51］ Dumonteil N， Meredith IT， Blackman DJ， et al. Insights into the need for permanent pacemaker following implantation of the repositionable Lotus valve for transcatheter aortic valve replace-ment in 250 patients： results from the REPRISE Ⅱ trial with extended cohort［J］. EuroIntervention， 2017， 13： 796- 803.
［52］ Kebler M， Gonska B， Seeger J， et al. Predictors of permanent pacemaker implantation after transfemoral aortic valve implantation with the Lotus valve［J］. Am Heart J， 2017， 192： 57- 63.
［53］ Gonska B， Seeger J， KeBler M， et al. Predictors for permanent pacemaker implantation in patients undergoing transfemoral aortic valve implantation with the Edwards Sapien 3 valve［J］. Clin Res Cardiol， 2017， 106： 590- 597.
［54］ Sager SJ， Damluji AA， Cohen JA， et al. Transient and persistent conduction abnormalities following transcatheter aortic valve replacement with the Edwards- Sapien prosthesis： a comparison between antegrade vs. retrograde approaches［J］. J Interv Card Electrophysiol， 2016， 47： 143- 151.
［55］ Sideris S， Benetos G， Toutouzas K， et al. Outcomes of same day pacemaker implantation after TAVI［J］. Pacing Clin Electrophysiol， 2016， 39： 690- 695.
［56］ Meduri C， Kereiakes DJ， Rajagopal V， et al. Pacemaker implantation and dependency after transcatheter aortic valve replacement in the REPRISE Ⅲ trial［J］. J Am Heart Assoc， 2019， 8： e012594.
［57］ Summers MR， Leon MB， Smith CR， et al. Prosthetic valve endocarditis after TAVR and SAVR： insights from the PARTNER trials［J］. Circulation， 2019， 140： 1984- 1994.
［58］ Athappan G， Patvardhan E， Tuzcu EM， et al. Incidence， predictors， and outcomes of aortic regurgitation after transcatheter aortic valve replacement： meta- analysis and systematic review of literature［J］. J Am Coll Cardiol， 2013， 61： 1585- 1595.
［59］ Blackman DJ， Meredith IT， Dumonteil N， et al. Predictors of paravalvular regurgitation after implantation of the fully repositio-nable and retrievable lotus transcatheter aortic valve（from the REPRISE Ⅱ trial extended cohort）［J］. Am J Cardiol， 2017， 120： 292- 299.
［60］ Pibarot P， Hahn RT， Weissman NJ， et al. Assessment of paravalvular regurgitation following TAVR： a proposal of unifying grading scheme［J］. JACC Cardiovasc Imaging， 2015， 8： 340- 360.
［61］ Ribeiro HB， Webb JG， Makkar RR， et al. Predictive factors， management， and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation insights from a large multicenter registry［J］. J Am Coll Cardiol， 2013， 62： 1552- 1562.
［62］ 朱 灏，任晓敏，蔡金赞，等． 经导管主动脉瓣置换术后新发心房颤动的系统评价［J］． 中国循环杂志， 2016， 31：1106- 1110．
［63］ Hengstenberg C， Chandrasekhar J， Sartori S， et al. Impact of pre- existing or new- onset atrial fibrillation on 30- day clinical outcomes following transcatheter aortic valve replacement： results from the BRAVO 3 randomized trial［J］. Catheter Cardiovasc Interv， 2017， 90： 1027- 1037.
［64］ Sondergaard L， De Backer O， Kofoed KF， et al. Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic valves［J］. Eur Heart J， 2017， 38： 2201- 2207.
［65］ Ducrocq G， Francis F， Serfaty JM， et al. Vascular compli- cations of transfemoral aortic valve implantation with the Edwards SAPIEN prosthesis： incidence and impact on outcome［J］. EuroIntervention， 2010， 5： 666- 672.
［66］ Holmes DJ， Nishimura RA， Grover FL， et al. Annual outcomes with transcatheter valve therapy： from the STS/ACC TVT registry［J］. J Am Coll Cardiol， 2015， 66： 2813- 2823.
［67］ Landes U， Barsheshet A， Finkelstein A， et al. Temporal trends in transcatheter aortic valve implantation， 2008- 2014： patient characteristics， procedural issues， and clinical outcome［J］. Clin Cardiol， 2017， 40： 82- 88.
［68］ Pressler A， Christle JW， Lechner B， et al. Exercise training improves exercise capacity and quality of Life after transcatheter aortic valve implantation： a randomized pilot trial［J］. Am Heart J， 2016， 182： 44- 53.
［69］ Pressler A， Forschner L， Hummel J， et al. Long- term effect of exercise training in patients after transcatheter aortic valve implantation： follow- up of the SPORT： TAVI randomised pilot study［J］. Eur J Prev Cardiol， 2018， 25： 794- 801.
［70］ Edwards KS， Chow E， Dao C， et al. Impact of cognitive behavioral therapy on depression symptoms after transcatheter aortic valve replacement： a randomized controlled trial［J］. Int J Cardiol， 2020， 321： 61- 68.

相似文献/References:

[1]邢利菲,韩 宇,刘煜昊,等.自膨式Venus-A瓣膜和VitaFlow瓣膜治疗重度主动脉瓣狭窄的临床效果[J].介入放射学杂志,2022,31(08):756.
　XING Lifei,HAN Yu,LIU Yuhao,et al.Self-expanding Venus-A valve versus VitaFlow valve in the treatment of severe aortic stenosis： analysis of clinical effect[J].journal interventional radiology,2022,31(10):756.

备注/Memo

备注/Memo:
（收稿日期：2021- 09- 10）
（本文编辑：边 佶）
更新日期/Last Update: 2022-11-02